Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

NCT02469415 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped FDA Clinical Hold

Conditions

Leukemia

Interventions

DRUG: Pacritinib
DRUG: 5-azacitidine
DRUG: Decitabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]